the NCIC trial had a median survival of 7.4 months, although it was 7.9 months for patients enrolled on ECOG 1594, a trial comparing 3 third-generation doublets with cisplatin and paclitaxel published 14 years later. 2 Several strategies have
Search Results
Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee
EGFR-activating mutation or an ALK translocation is doublet chemotherapy (category 1). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) currently list docetaxel, paclitaxel, pemetrexed, vinorelbine
Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria
compared a combination of carboplatin and paclitaxel with single-agent chemotherapy (either gemcitabine or vinorelbine) in patients between ages 70 and 89 years. 43 In this study, median overall survival was better in the doublet arm, with a 4-month
Jaffer A. Ajani, Thomas A. D’Amico, Khaldoun Almhanna, David J. Bentrem, Stephen Besh, Joseph Chao, Prajnan Das, Crystal Denlinger, Paul Fanta, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kory Jasperson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, James A. Posey, George A. Poultsides, Aaron R. Sasson, Walter J. Scott, Vivian E. Strong, Thomas K. Varghese Jr, Mary Kay Washington, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, and Hema Sundar
follow-up of 18 months, median OS time was 23 months. 42 The rate of locoregional progression-free survival (PFS), PFS, and 3-year OS rates were 60%, 29%, and 37%, respectively. Definitive chemoradiation with carboplatin and paclitaxel was also well
Jeffrey Allen and Mohammad Jahanzeb
Edited by Kerrin G. Robinson
gemcitabine plus cisplatin as induction chemotherapy for stage III non-small cell lung cancer . Lung Cancer 2002 ; 35 : 319 – 327 . 20. De Marinis F Nelli F Migliorino MR . Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for
Thomas W. Flaig
presented at the 2018 Genitourinary Cancers Symposium. This trial of 542 patients compared pembrolizumab (200 mg every 3 weeks) with chemotherapy (vinflunine, paclitaxel, or docetaxel). 6 , 7 The overall response rates were higher with pembrolizumab than
David S. Ettinger, Mark Agulnik, Justin M. M. Cates, Mihaela Cristea, Crystal S. Denlinger, Keith D. Eaton, Panagiotis M. Fidias, David Gierada, Jon P. Gockerman, Charles R. Handorf, Renuka Iyer, Renato Lenzi, John Phay, Asif Rashid, Leonard Saltz, Lawrence N. Shulman, Jeffrey B. Smerage, Gauri R. Varadhachary, Jonathan S. Zager, and Weining (Ken) Zhen
carboplatin, gemcitabine, and paclitaxel followed by weekly paclitaxel was active and tolerable for patients with occult primary tumors and poor prognostic features. 59 Recently, Hainsworth et al. 63 , 64 reported that the combination of bevacizumab and
William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar
. 60 Preoperative Systemic Therapy in Patients With HER2 + Tumors: In women with HER2 + tumors treated with neoadjuvant chemotherapy, the addition of neoadjuvant trastuzumab to paclitaxel followed by chemotherapy with FEC (fluorouracil
David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, Mohammad Jahanzeb, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang
good PS. The CALGB 9633 trial assessed paclitaxel and carboplatin in patients with T2, N0, M0, stage IB lung cancer; 185 updated results have been reported. 186 , 187 In this trial, 344 patients (aged 34–81 years) were randomly assigned to either
David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, and Kristina M. Gregory
include platinum agents (cisplatin, carboplatin), taxanes (paclitaxel, docetaxel), vinorelbine, vinblastine, etoposide, pemetrexed, and gemcitabine. Combinations using many of these drugs produce 1-year survival rates of 30% to 40% and are superior to
